Tuesday, 20 May, 2025

Regeneron Acquires 23andMe for $256M, Pledges Ethical Use of Genetic Data

Regeneron Pharmaceuticals is set to acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction. The acquisition aims to enhance Regeneron's genomics-driven drug discovery by integrating 23andMe's extensive DNA database. Following a 2023 data breach affecting millions, Regeneron has committed to the ethical handling of customer genetic information. The deal, expected to finalize in Q3 2025, raises ongoing concerns about data privacy and ownership.